. 2019 Apr 26;7(1):67–81. doi: 10.1007/s40487-019-0094-x

Table 2.

Overall burden of AML

	Relapsed/refractory status^a			Treatment intensity			HMA monotherapy status^b			SCT status			FLT3-ITD status^c
	Overall (N = 75)	RR (n = 19)	Non-RR (n = 56)	Overall (N = 82)	High (n = 43)	Low (n = 39)	Overall (N = 39)	HMA mono (n = 24)	Non HMA^d (n = 15)	Overall (N = 82)	SCT (n = 10)	Non SCT (n = 72)	Overall (n = 54)	FLT3 (n = 7)	Non FLT3 (n = 47)
FACT-Leu
Physical well-being
Mean	16.4	13.0	17.6	15.9	16.3	15.4	15.4	13.0	19.3	15.9	15.1	16.0	16.2	12.0	16.2
P		0.0053			0.5227			0.0006			0.6781			0.0711
Effect size		0.729			0.142			1.063			0.141			0.730
Social well-being
Mean	18.1	17.0	18.4	18.0	17.8	18.2	18.2	17.0	19.9	18.0	17.5	18.1	17.3	18.2	17.1
P		0.3189			0.7846			0.0851			0.7495			0.5925
Effect size		0.266			0.061			0.567			0.109			0.220
Emotional well-being
Mean	12.1	11.7	12.3	12.0	12.0	12.0	12.0	11.7	12.5	12.0	9.5	12.3	11.7	10.3	11.9
P		0.6351			0.9818			0.5257			0.0664			0.3820
Effect size		0.127			0.005			0.213			0.619			0.358
Functional well-being
Mean	14.9	14.3	15.1	15.1	14.6	15.7	15.7	15.1	16.7	15.1	13.4	15.4	14.2	13.3	14.4
P		0.5679			0.3099			0.3398			0.2530			0.5927
Effect size		0.153			0.226			0.319			0.388			0.220
FACT-G
Mean	61.5	56.0	63.3	61.0	60.7	61.3	61.3	56.8	68.5	61.0	55.5	61.7	59.4	53.8	60.3
P		0.0842			0.8675			0.0143			0.2360			0.3003
Effect size		0.458			0.037			0.790			0.402			0.423
Leukemia-specific
Mean	39.4	36.5	40.4	38.3	39.0	37.5	37.5	33.1	44.4	38.3	36.8	38.5	38.7	31.7	39.7
P		0.1788			0.5314			0.0007			0.6545			0.0717
Effect size		0.358			0.140			1.050			0.152			0.729
Trial outcome index
Mean	70.7	63.8	73.0	69.3	69.9	68.6	68.6	61.2	80.5	69.3	65.3	69.8	69.1	70.9	57.0
P		0.0802			0.7688			0.0007			0.4965			0.0803
Effect size		0.464			0.066			1.055			0.231			0.708
Overall
Mean	100.9	92.5	103.7	99.3	99.7	98.8	98.8	89.9	112.9	99.3	92.3	100.2	98.1	85.5	100.0
P		0.0982			0.8639			0.0021			0.3517			0.1484
Effect size		0.439			0.038			0.971			0.316			0.588
CTSQ
Therapy expectations
Mean	66.9	64.7	67.7	65.9	68.0	63.4	63.4	54.3	77.3	65.9	72.0	65.0	66.1	67.1	66.0
P		0.6172			0.3409			0.0007			0.3396			0.8946
Effect size		0.134			0.213			1.061			0.325			0.054
Therapy satisfaction
Mean	64.9	60.3	66.5	64.1	65.7	62.3	62.3	56.3	71.9	64.1	65.0	63.9	66.1	62.2	66.7
P		0.1581			0.3402			0.0029			0.8474			0.4765
Effect size		0.376			0.212			0.943			0.066			0.292
Feelings about side effects
Mean	46.5	45.1	47.0	47.0	44.8	49.5	49.5	49.5	49.6	47.0	44.4	47.4	47.1	40.2	48.1
P		0.6313			0.1439			0.9752			0.5464			0.1810
Effect size		0.129			0.326			0.011			0.205			0.545
EQ-5D-VAS
Mean	61.2	58.6	62.1	62.0	62.5	61.4	61.4	58.7	65.9	62.0	57.2	62.7	61.6	47.6	63.7
P		0.5092			0.7899			0.2627			0.4100			0.0428
Effect size		0.177			0.060			0.381			0.280			0.816
EQ-5D-3L
Mean	0.74	0.71	0.75	0.74	0.74	0.74	0.74	0.70	0.79	0.74	0.65	0.75	0.74	0.64	0.76
P		0.5148			0.9329			0.0928			0.1288			0.1629
Effect size		0.175			0.019			0.558			0.514			0.568

Mean scores shown

Bold text reflects where the P value is < 0.05

CTSQ Cancer Therapy Satisfaction Questionnaire, EQ-5D-VAS 5-Dimension EuroQol Questionnaire with Visual Analog Scale, EQ-5D-3L EuroQoL 5-dimension health-related quality of life measure, FACT-G functional assessment of cancer therapy-general, FACT-Leu functional Assessment of Cancer Therapy-Leukemia, RR relapsed/refractory, FLT3-ITD FMS-like tyrosine kinase-3 internal tandem duplication, HMA hypomethylating agent, SCT stem cell transplant, AML acute myeloid leukemia

^aSeven patients excluded as not on therapy currently

^bForty-three patients excluded as not receiving a high-intensity therapy

^cTwenty-eight patients did not undergo cytogenetic testing, FLT3 status unknown

^dPatients are receiving other AML treatment